Literature DB >> 29182491

Improved Lung Function after Sinus Surgery in Cystic Fibrosis Patients with Moderate Obstruction.

Sabrina Khalfoun1, Dmitry Tumin2, Maroun Ghossein3, Meredith Lind4, Don Hayes1, Stephen Kirkby1.   

Abstract

Objectives Cystic fibrosis (CF) is characterized by infection and inflammation of the sinorespiratory tract. Functional endoscopic sinus surgery (FESS) is an option for patients with severe sinusitis. We sought to evaluate pulmonary function testing after FESS in pediatric and adult patients with CF. Study Design Retrospective chart review using data from all patients with CF who underwent FESS from January 2009 to July 2014. Setting Patients were from a single institution. Subjects and Methods Data were extracted for 181 patients and 320 surgeries. Lung function data, including the forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC, were retrieved within 1 year before and after surgery. Mixed-effects regression was used to compare FEV1 trajectories before and after surgery. The effect of surgery was stratified by presurgery FEV1 to compare patients with mild/no lung disease (FEV1 >80%) and moderate/severe lung disease (FEV1 <80%). Results Of the 181 patients reviewed, 131 with primary FESS had FEV1 data. Presurgery average age was 16 years (95% confidence interval [CI], 14.27-17.73), and FEV1 mean was 85% (95% CI, 81.02-88.98). There were 88 patients with FEV1 >80% and 43 patients with FEV1 <80%. For the entire cohort, lung function did not change related to FESS. Among patients with FEV1 <80%, FEV1 declined presurgery by 3.5% per year (95% CI, -6.1% to -0.8%; P = .010), which halted after surgery with these patients, then showing no subsequent change in FEV1 (95% CI, 0.9%-3.7%; P = .240). No benefit was identified for patients with FEV1 >80%. Conclusion Pulmonary function testing improved in patients with moderate/severe lung disease 1 year following FESS. This suggests FESS may benefit pulmonary outcomes.

Entities:  

Keywords:  quality of life; rhinitis; sinusitis; spirometry

Mesh:

Year:  2017        PMID: 29182491     DOI: 10.1177/0194599817739284

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  5 in total

1.  Streamlining care in cystic fibrosis: survey of otolaryngologist, pulmonologist, and patient experiences.

Authors:  Zainab Farzal; Kelly M Dean; Satyan B Sreenath; Sarah E Hodge; Brian D Thorp; Charles S Ebert; Adam M Zanation; Brent A Senior; Adam J Kimple
Journal:  Int Forum Allergy Rhinol       Date:  2020-01-17       Impact factor: 3.858

Review 2.  Cystic Fibrosis.

Authors:  Kimberly M Dickinson; Joseph M Collaco
Journal:  Pediatr Rev       Date:  2021-02

3.  Longitudinal analysis of sinus microbiota post endoscopic surgery in patients with cystic fibrosis and chronic rhinosinusitis: a pilot study.

Authors:  Brett Wagner Mackenzie; Camila Dassi; Anitha Vivekanandan; Melissa Zoing; Richard G Douglas; Kristi Biswas
Journal:  Respir Res       Date:  2021-04-13

4.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

Review 5.  Chronic rhinosinusitis in cystic fibrosis: a review of therapeutic options.

Authors:  Joanna Krajewska; Krzysztof Zub; Adam Słowikowski; Tomasz Zatoński
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-07-22       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.